Tarsus Pharmaceuticals, Inc. (TARS): Total Liabilities
$218.73M
As of 2025-12-31
$264.41M
As of 2026-06-30
+84.3%
3-year compound annual growth
+105.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $218.73M | +43.5% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $152.46M | +122.6% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $68.50M | +95.9% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $34.96M | +187.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $12.18M | +103.2% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $5.99M | +552.0% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $919.0K | n/a | 2021-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗